Skip to main content
Lynne Abruzzo, MD, Medical Genetics, Columbus, OH, Ohio State University Wexner Medical Center

LynneV.AbruzzoMD

Medical Genetics Columbus, OH

Clinical Cytogenetics

Professor, Pathology, Ohio State University College of Medicine

Dr. Abruzzo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Abruzzo's full profile

Already have an account?

Education & Training

  • University of Michigan Health System
    University of Michigan Health SystemResidency, Pathology-Anatomic and Clinical, 1986 - 1990
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1986

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2013 - 2025
  • SC State Medical License
    SC State Medical License 2024 - 2025
  • GA State Medical License
    GA State Medical License 2022 - 2025
  • DC State Medical License
    DC State Medical License 1994 - 2014
  • TX State Medical License
    TX State Medical License 2000 - 2014
  • MD State Medical License
    MD State Medical License 1990 - 2014
  • American Board of Pathology Anatomic Pathology & Clinical Pathology
  • American Board of Pathology Hematology
  • American Board of Medical Genetics and Genomics Clinical Cytogenetics and Genomics
  • American Board of Medical Genetics and Genomics Laboratory Genetics and Genomics

Publications & Presentations

PubMed

Journal Articles

  • Trisomy 12 Chronic Lymphocytic Leukemia Expresses a Unique Set of Activated and Targetable Pathways  
    Michael J Keating, Lynne V Abruzzo, Haematologica

Lectures

  • Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • FCR Still an Option in IGHV-Unmutated CLL?
    FCR Still an Option in IGHV-Unmutated CLL?October 8th, 2019
  • Deletion 20q in CLL May Represent Disease Progression
    Deletion 20q in CLL May Represent Disease ProgressionMay 28th, 2015

Grant Support

  • Validation Of RNA And DNA Biomarkers Of Prognosis In Chronic Lymphocytic LeukemiaNational Cancer Institute2006–2008

Hospital Affiliations